1. Academic Validation
  2. Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety

Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety

  • Bioorg Med Chem Lett. 2019 Jan 1;29(1):97-102. doi: 10.1016/j.bmcl.2018.11.002.
T G Shruthi 1 Sumesh Eswaran 1 Prasad Shivarudraiah 1 Shridhar Narayanan 2 Sangeetha Subramanian 3
Affiliations

Affiliations

  • 1 Anthem Biosciences Pvt. Ltd, 49 Bommasandra Industrial Area, Bommasandra, Bengaluru 560099, Karnataka, India.
  • 2 Foundation for Neglected Disease Research, Bengaluru 562157, Karnataka, India.
  • 3 SBST, Vellore Institute of Technology, Vellore 632014, Tamil Nadu, India. Electronic address: sangeethasubramanian@vit.ac.in.
Abstract

Tuberculosis is the infectious disease caused by mycobacterium tuberculosis (Mtb), responsible for the utmost number of deaths annually across the world. Herein, twenty-one new substituted 1,2,4-oxadiazol-3-ylmethyl-piperazin-1-yl-quinoline derivatives were designed and synthesized through multistep synthesis followed by in vitro evaluation of their antitubercular potential against Mtb WT H37Rv. The compound QD-18 was found to be promising with MIC value of 0.5 µg/ml and QD-19 to QD-21 were also remarkable with MIC value of 0.25 µg/ml. Additionally, we have carried out experiments to confirm the metabolic stability, cytotoxicity and pharmacokinetics of these compounds along with kill kinetics of QD-18. These compounds were found to be orally bioavailable and highly effective. Altogether, these results indicate that QD-18, QD-19, QD-20 and QD-21 are promising lead compounds for the development of a novel chemical class of antitubercular drugs.

Keywords

Antitubercular activity; Bioavailability; Cytotoxicity; Oxadiazole; Quinoline.

Figures